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Background
The tragic death of a Dutch patient due to Duvenhage virus
infection acquired after bat exposure in Kenya during 2007
emphasizes the potential dangers associated with ecotourism,
underscores the role of Chiroptera as reservoirs of emerging
infectious diseases, and highlights modern attempts to prevent and
treat these zoonotic diseases.
The patient in this incident, a physician from The Netherlands,
was a visitor to a game park in eastern Kenya, and had not been
previously vaccinated against rabies. Often, many travelers abroad
may not be well versed in local environmental conditions. Well
before expected departure, travel medicine consultants should
discuss both generic and country-specific risks with their clients.
For maximum benefit, several biologics require administration a
month in advance of departure, such as rabies pre-exposure
immunization. Besides primary vaccination suggestions, and
health insurance considerations for emergency care abroad or
medical evacuation as needed, basic education is necessary
concerning realistic public health concerns, especially in develop-
ing countries. Selective positive social behaviors should be
promoted, especially as related to personal interactions with
animals, both domestic and wild. Greater appreciation of animals
from a distance is ideal, rather than any personal provocations. If
animal bites or scratches do occur, immediate thorough washing
of wounds with soap and clean water is valuable, followed by
careful biomedical evaluation. While the latter was attempted in
this particular Kenyan incident, the global implications of bat
rabies were not appreciated.
Unlike the epidemiological situation in Europe and the
developed world, rabid dogs remain responsible for the vast
majority of human rabies cases in other parts of the world. For this
reason, less attention is paid to infections acquired from other
mammals, such as wildlife. With the exception of Antarctica, bat
rabies occurs on all continents. The existence of lyssaviruses
associated with infected Chiroptera in Africa has been document-
ed for several decades [1]. Although surveillance is often limited or
lacking, multiple studies to date suggest that bat rabies is much
more widespread throughout Africa, and other continents, than is
commonly communicated. In contrast to bites from mammalian
carnivores, such as dogs, resulting injuries after even superficial
direct contact with bats may appear rather trivial by comparison,
as illustrated in this patient, with only superficial wounds noticed
on her nose. In another typical example from Texas in 2006, a
teenager died from rabies 1 month after a report of a bat that had
awakened him, after landing upon his face [2]. Clearly, based
upon both experimental and epidemiological criteria, any
probable likelihood for bona fide transdermal or mucosal
exposures to a bat is a reasonable consideration for rabies
prophylaxis, regardless of geographical locality. Confusion in the
use of specific viral taxonomy related to the presence or absence of
‘‘rabies virus’’ per se, versus other ‘‘lyssaviruses’’, or bio-political
considerations over so-called ‘‘rabies-free’’ areas, are largely
irrelevant to the health provider and traveler alike, and pale in
the face of obvious public health concerns when ignored or
misunderstood, in the wake of volant reservoirs. To simplify: rabies
is an acute progressive encephalitis; the clear majority of cases
occur after animal bite; lyssaviruses are the neurotropic etiological
agents that cause rabies; rabies virus is only one of at least 11 types
of lyssavirus; rabies is a preventable infectious disease; any
suggestions of ‘‘rabies-like diseases’’ are obvious misnomers that
only obfuscate health communications.
Findings
The reported incubation period in the Dutch patient of
approximately 3 weeks after bat exposure to her face falls within
the expected 1–3 month estimate for rabies. In the light of a
suggestive history and compatible clinical signs, human antemor-
tem diagnostics attempt to define specific lyssavirus antigens,
antibodies, or amplicons from clinical material, including skin
biopsy, serum, cerebrospinal fluid, and saliva, but rarely follow a
discrete predictable course given the diversity of lyssavirus variant,
route, dose, and patient parameters. Host infection and immunity
related to lyssaviruses are complex, multigenic events [3]. After
exposure, viral RNA may persist locally in tissues for days to weeks
[4]. Apparent abortion of productive infections and induction of
virus-neutralizing antibodies in seemingly healthy animal popula-
tions have been detected historically in taxa as diverse as bats and
mongoose [5,6]. Such observations have even been extended to a
few human populations at risk, such as those involved with animal
trapping [7,8]. The innate and adaptive mechanisms against
rabies are poorly understood, which include outcomes of
protective immunity sans overt illness, clinical recovery, or death
[9]. Animals have recovered after experimental rabies, usually
with frank neurological sequellae [10]. Spontaneous recoveries
after overt illness, with involvement of the central nervous system,
have not been well documented in human rabies infections.
However, considering the genetic and antigenic diversity of
lyssaviruses, coupled with the plasticity of the mammalian immune
response, recovery from such a lyssavirus-induced encephalitis is
conceptually appealing, albeit rare in actuality. The fact that as
little as a single base change in the genome equates with the
difference between a pathogenic virus and a highly attenuated
agent strongly suggests that a continuum exists between virulence
and immunity resulting from more ‘‘temperate’’ lyssaviruses, at
least in experimental settings [11,12].
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advent of encephalitis. Rabies immunization is highly effective, if
administered to those at risk before exposure, or promptly and
properly after viral exposure. Typical human postexposure
prophylaxis entails immediate wound care, the infiltration of
rabies immune globulin in and around the bite, and the parenteral
inoculation of cell culture vaccine on days 0, 3, 7, 14, and 28
(although the absolute number of doses, routes, and schedules may
vary globally). Postexposure prophylaxis should begin as soon as
possible after exposure, and should not be withheld even with the
passage of time after a bite, as virus may reside locally for several
days after exposure, even though the likely effectiveness of
intervention is expected to decline as virus accesses the nervous
system. Prophylaxis is not appropriate in rabies patients after the
advent of clinical signs. Such utilization has not been shown to be
effective in either actual clinical settings or in experimental
applications with laboratory animals. As such, administration of
prophylaxis concomitant with illness onset offers false hope to
families without substantiation and in the context of a developing
country would waste expensive valuable biologics. Moreover, such
vaccinations can interfere with diagnostic testing on patient sera,
as well as confound interpretations if experimental therapeutics are
elected. Critically, from the standpoint of acute outcome,
application of such inactivated commercial biologics may skew
host immunity from a more appropriate response and actually
threaten patient health, within the realms of the ‘‘early death’’
phenomenon [13].
The dual administration of human rabies immune globulin and
vaccine, and institution of experimental treatment, in this critically
ill patient was a desperate attempt to intervene against an
otherwise fatal disease. Human rabies treatment, as practiced
favorably upon an unvaccinated 15-year-old girl bitten on her
finger by a bat in Wisconsin during 2004, is challenging,
expensive, and no simple panacea. While not successful in this
Dutch case or in several other patients as can be gleaned from the
Wisconsin protocol patient registry, likely differences in etiology,
exposure route, infectious dose, host factors, timing of interven-
tion, nosocomial issues, and other complex variables prevent a
simple comparison to the so-called original Milwaukee protocol.
At a minimum, proper palliative comfort care needs to be offered
to all rabies patients. The value of any experimental intervention
for this disease remains to be proven ultimately based upon further
scientific insights, the tincture of time, and a gradual accumulation
of successes from those that dare to risk non-conventional
approaches and attempt to overcome the near impossible statistics
associated with this malady [14,15].
Implications
The failure of a successful outcome with this particular patient
does showcase one fatal conundrum in the state of the art of
research in rabies therapeutics. Animal models have played a large
role in the experimental development of biologics against rabies,
especially in vaccine production. However, to design a successful
intervention against clinical rabies, new paradigms are needed. A
historical focus upon fixed, laboratory rabies viruses, intracerebral
inoculation, and the utilization of laboratory mice alone have
provided some insights into basic pathogenesis, but are quite
limited from the standpoint of street virus heterogeneity, more
natural routes of exposure, and logistical limitations of medical
care in small-bodied mammalian subjects. The utilization of more
appropriate species would allow greater use of intensive,
synergistic clinical intervention in rabid subjects at different stages
of disease onset, as would be experienced in a sophisticated
intensive care setting, coupled with promising compounds derived
from a more rational, targeted approach in anti-viral design
[16,17].
Future Directions
The lessons learned from this fatal human case after exposure to
a rabid African bat are multiple, including the following: improved
support for a multidisciplinary approach towards relevant health
communications on the existence of emerging pathogens abroad,
especially as related to bats and the prevention of such deleterious
outcomes; greater basic research on pathogenic mechanisms
associated with such agents, particularly as regards an extension
to proximate biomedical interventions, once clinical signs
manifest; and an integrated applied outreach on the ecology of
zoonotic and vector-borne infectious diseases for improved long-
term prevention and control strategies, within an encompassing
‘‘one health’’ philosophy.
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